Plasma testosterone concentrations in asthmatic men treated with glucocorticoids.

Reid, Ian R.; Ibbertson, H. K.; France, John T.; Pybus, John

doi:10.1136/bmj.291.6495.574

Cited by 131 publications

(42 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 Diagnosis of AI was based on the detection of a unilateral adrenal mass by noninvasive imaging methods of the abdomen, performed for unrelated disease. The exclusion criteria were: (i) past or current history of hypogonadism (testosterone levels < 9·4 nmol/l) 18 and of other diseases known to affect bone metabolism (i.e.…”

Section: Subjectsmentioning

confidence: 99%

Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures

Chiodini

Viti²,

Coletti

et al. 2009

Clinical Endocrinology

View full text Add to dashboard Cite

SummaryObjective Subclinical hypercortisolism (SH) is suggested to exert a deleterious effect on bone. This effect and the role of gonadal status in male subjects are not fully elucidated. We evaluated bone mineral density (BMD) and prevalence of vertebral fractures in eugonadal male subjects with adrenal incidentalomas (AI) and without SH. Design This 12-month observational multicentre study was performed between January and December 2006 on inpatient basis in three referral Italian centres. Patients Eighty-eight consecutive eugonadal male patients with AI and 90 matched control subjects were studied. Measurements All subjects underwent the determination of BMD by dual-energy X-ray absorptiometry at lumbar spine (LS) and femoral neck (FN), and spinal radiograph. In AI patients SH was diagnosed in the presence of two of the following: urinary free cortisol > 193·1 nmol/l, cortisol after 1 mg dexamethasone suppression test > 82·8 nmol/l, ACTH levels < 2·2 pmol/l. Results As compared to patients without SH (SH-, n = 66) and controls, patients with SH (SH+, n = 22) had lower BMD at LS ( Z -score: SH+, -1·04 ± 1·84; SH-, 0·19 ± 1·34, Controls 0·20 ± 1·28, P = 0·001 and FN ( Z -score: SH+, -0·63 ± 1·01; SH-, 0·01 ± 1·01, Controls 0·26 ± 1·06, P = 0·002) and higher prevalence of fractures (SH+, 72·7%; SH-, 21·2%, Controls 20·0%, P = 0·0001). Multivariable analyses showed that SH was associated to BMD at LS ( β = -0·378, P = 0·0001) and vertebral fractures (OR = 7·81, 95% CI 1·96 -31·17, P = 0·004). ConclusionIn eugonadal male patients with AI, SH is associated with low BMD and high prevalence of vertebral fractures.

show abstract

Section: Subjectsmentioning

confidence: 99%

Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures

Chiodini

Viti²,

Coletti

et al. 2009

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Higher doses of testosterone were also effective in reducing the MP-induced upregulation of the known muscle atrophy genes FOXO1, MAFbx and REDD1. When taken together with the findings that the trauma of acute SCI and that of glucocorticoid administration both serve to reduce circulating testosterone levels in men, [17][18][19] our findings suggest the possibility that there may be a clinical benefit to the use of replacement doses of testosterone in spinal cord-injured men administered high-dose MP therapy at the time of injury. This possibility will be an important area for future study.…”

Section: Discussionmentioning

confidence: 96%

“…10,[14][15] The protective actions of endogenous testosterone are likely to be diminished after SCI in men, particularly during the first few weeks or months after acute injury, because circulating levels of testosterone are often markedly reduced. 16,17 Administration of glucocorticoid medications themselves have been associated with reduced circulating levels of testosterone, and these agents may produce a state of relative or absolute hypogonadism, 18,19 which may be speculated to worsen any state of hypogonadism already present as a result of the stress of trauma or other medical conditions associated with SCI.…”

Section: Introductionmentioning

confidence: 99%

Testosterone reduced methylprednisolone-induced muscle atrophy in spinal cord-injured rats

Collier

Pan

et al. 2011

Spinal Cord

View full text Add to dashboard Cite

Study design: Male rats with complete transections of the spinal cord were administered vehicle or methylprednisolone (MP) for 24 h, with or without infusion, for 7 days, of testosterone at either a replacement or low pharmacological doses. Muscles were collected at 7 days after SCI. Objective: The objective of this study is to determine, in a rat model of complete spinal cord transection, whether testosterone reduces muscle atrophy or upregulates muscle atrophy-linked genes, induced by 24 h of MP administration at doses comparable to those prescribed in man during the period immediately following acute spinal cord injury (SCI) in an attempt to preserve neurological function. Results: MP significantly reduced the mass of triceps, soleus and plantaris, and significantly increased expression of genes that promote atrophy. Testosterone significantly reduced muscle atrophy induced by MP, but did not prevent it; there was no difference between low-or high-dose testosterone in reducing MP-induced muscle loss. High-dose testosterone reduced expression of muscle atrophy genes more than did low dose. Testosterone-induced declines in mRNA levels for these atrophy-associated genes did not correlate well with protection against MP-induced muscle atrophy. Conclusions: MP induces marked and lasting changes in the biology of muscle that persisted for at least 7 days, or 6 days after MP has been eliminated from the body. Testosterone partially protected against muscle atrophy and gene expression changes caused by 1 day of MP.

show abstract

“…Among these drugs, glucocorticoids, stand out (24) inducing the reduction of cFT by combined actions both at the testicular and at the hypothalamic-pituitary level, being these adverse effects in the production of testosterone dose dependent (25)(26)(27)(28).…”

Section: Discussionmentioning

confidence: 99%

Laboratory diagnosis of late-onset male hypogonadism andropause

Clapauch¹,

Carmo²,

Marinheiro

et al. 2008

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

OBJECTIVES: To evaluate which factors influence the laboratorial diagnosis of late-onset male hypogonadism (LOH). METHODS: Total testosterone (TT), SHBG and albumin were measured in 216 men aged 52-84 years. The laboratorial definition of LOH was two values of calculated free testosterone (cFT) <6.5 ng/dl, according to Vermeulen's formula. RESULTS: At the first blood test, cFT was <6.5 ng/dl in 27% of the men. Laboratorial LOH (confirmed by two tests) was present in 19%, but TT levels were low in only 4.1%. Age influenced TT (p=0.0051) as well as BMI; 23.5% of patients > 70 years and 38.9% of the obese men who had TT within the reference range were, in fact, hypogonadal. CONCLUSION: Especially in obese men and in those > 70 years old, SHBG dosage is important to calculate FT levels and diagnose hypogonadism.

show abstract

Plasma testosterone concentrations in asthmatic men treated with glucocorticoids.

Cited by 131 publications

References 5 publications

Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures

Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures

Testosterone reduced methylprednisolone-induced muscle atrophy in spinal cord-injured rats

Laboratory diagnosis of late-onset male hypogonadism andropause

Contact Info

Product

Resources

About